secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2022-02-18T23:59:59+00:00
Accession:  0001193125-22-046719
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics appoints Harlan Waksal as Executive Chair; adopts inducement award plan
--------------------------------------------------------------------------------

- Harlan Waksal appointed as Class II director, Chairperson, and Executive Chair; base salary $200,000.
- Waksal receives option to purchase 520,000 shares at $4.21, vesting based on market cap targets over 5 years.
- CEO Maria Palasis granted option for 175,000 shares; both executives eligible for 1% of market cap bonus on change in control ≥ $750M.
- Lyra adopts 2022 Inducement Award Plan reserving 520,000 shares for new hires under Nasdaq Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/0001193125-22-046719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-046719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer